Novo Nordisk Market Cap 2010-2023 | NVO

Novo Nordisk market cap history and chart from 2010 to 2023. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Novo Nordisk market cap as of April 18, 2024 is $550.84B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $550.845B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.775B 118.03
Johnson & Johnson (JNJ) United States $351.202B 13.93
Merck (MRK) United States $317.211B 83.49
AbbVie (ABBV) United States $291.555B 14.82
AstraZeneca (AZN) United Kingdom $211.944B 18.78
Novartis AG (NVS) Switzerland $196.211B 13.59
Pfizer (PFE) United States $143.772B 13.87
Sanofi (SNY) $114.819B 10.34
Innoviva (INVA) United States $0.929B 6.56